Clinical Trial

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium + oxaliplatin (SOX therapy) in PD-L1 CPS positive, elderly (≥70years old), pStage III gastric cancer (including esophagogastric junction cancer) after D2 dissection.
Trial Details
NCT Number NCT06238167
Lead Sponsor First Affiliated Hospital of Wenzhou Medical University
Conditions Gastric Cancer
Enrollment 40 participants
Start Date 2024-04-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-02